Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases
Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain Metastases
Breast Cancer Stage IV
DRUG: Trastuzumab deruxtecan
Reponse rate of brain metastases to trastuzumab-deruxtecan, measured according to RANO-BM criteria, From date of randomization until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed up to 36 months
Progression-free survival, Time from inclusion until progression, From date of randomization until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed up to 36 months|Overall Survival, Time from inclusion until death of any cause, From date of randomization until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed up to 36 months|Safety of trastuzumab deruxtecan in patients with active brain metastases, Assessment of treatment-emerging adverse events, From date of randomization until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed up to 36 months
T-DXd will be administered at a dose of 5.4 mg/kg body weight once every three weeks in patients with newly diagnosed or progressive HER2 positive breast cancer brain metastases. Response rate by RANO-BM is defined the primary study endpoint.